 |
The Journal of Neuroscience, February 23, 2005, 25(8):2132-2137; doi:10.1523/JNEUROSCI.3718-04.2005
Previous Article | Next Article 
BRIEF COMMUNICATION
3,4-Dihydroxyphenylalanine Reverses the Motor Deficits in Pitx3-Deficient Aphakia Mice: Behavioral Characterization of a Novel Genetic Model of Parkinson's Disease
Dong-Youn Hwang,1
Sheila M. Fleming,3
Paul Ardayfio,1
Taylor Moran-Gates,2
Hansoo Kim,1
Frank I. Tarazi,2
Marie-Francoise Chesselet,3 and
Kwang-Soo Kim1
1Molecular Neurobiology Laboratory and 2Psychiatric Neuroscience Laboratory, McLean Hospital and Harvard Medical School, Belmont, Massachusetts 02478, and 3Departments of Neurology and Neurobiology, The David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California 90095-1769
Parkinson's disease (PD) is a neurodegenerative disease characterized by a loss of dopaminergic neurons in the substantia nigra. There is a need for genetic animal models of PD for screening and in vivo testing of novel restorative therapeutic agents. Although current genetic models of PD produce behavioral impairment and nigrostriatal dysfunction, they do not reproduce the loss of midbrain dopaminergic neurons and 3,4-dihydroxyphenylalanine (L-DOPA) reversible behavioral deficits. Here, we demonstrate that Pitx3-deficient aphakia (ak) mice, which have been shown previously to exhibit a major loss of substantia nigra dopaminergic neurons, display motor deficits that are reversed by L-DOPA and evidence of "dopaminergic supersensitivity" in the striatum. Thus, ak mice represent a novel genetic model exhibiting useful characteristics to test the efficacy of symptomatic therapies for PD and to study the functional changes in the striatum after dopamine depletion and L-DOPA treatment.
Key words: Parkinson's disease; substantia nigra; aphakia mouse; Pitx3; dopaminergic neuron; animal model
Received Sep 8, 2004;
revised January 11, 2005;
accepted January 11, 2005.
This article has been cited by other articles:

|
 |

|
 |
 
X.-H. Lu, S. M. Fleming, B. Meurers, L. C. Ackerson, F. Mortazavi, V. Lo, D. Hernandez, D. Sulzer, G. R. Jackson, N. T. Maidment, et al.
Bacterial Artificial Chromosome Transgenic Mice Expressing a Truncated Mutant Parkin Exhibit Age-Dependent Hypokinetic Motor Deficits, Dopaminergic Neuron Degeneration, and Accumulation of Proteinase K-Resistant {alpha}-Synuclein
J. Neurosci.,
February 18, 2009;
29(7):
1962 - 1976.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Chou, N. Maidment, R. Klintenberg, J. E. Casida, S. Li, A. G. Fitzmaurice, P.-O. Fernagut, F. Mortazavi, M.-F. Chesselet, and J. M. Bronstein
Ziram Causes Dopaminergic Cell Damage by Inhibiting E1 Ligase of the Proteasome
J. Biol. Chem.,
December 12, 2008;
283(50):
34696 - 34703.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. S. Rommelfanger, G. L. Edwards, K. G. Freeman, L. C. Liles, G. W. Miller, and D. Weinshenker
Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice
PNAS,
August 21, 2007;
104(34):
13804 - 13809.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|